Bausch Health Companies Inc.

NYSE:BHC 주식 보고서

시가총액: US$2.5b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Bausch Health Companies 관리

관리 기준 확인 2/4

Bausch Health Companies' CEO는 Tom Appio, May2022 에 임명되었습니다 의 임기는 2.08 년입니다. 총 연간 보상은 $ 15.88M, 7.4% 로 구성됩니다. 7.4% 급여 및 92.6% 보너스(회사 주식 및 옵션 포함). 는 $ 2.72M 가치에 해당하는 회사 주식의 0.11% 직접 소유합니다. 2.72M. 경영진과 이사회의 평균 재임 기간은 각각 2.3 년과 7.9 년입니다.

주요 정보

Tom Appio

최고 경영자

US$15.9m

총 보상

CEO 급여 비율7.4%
CEO 임기2.1yrs
CEO 소유권0.1%
경영진 평균 재임 기간2.3yrs
이사회 평균 재임 기간7.9yrs

최근 관리 업데이트

Recent updates

The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

May 21
The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results

May 07

Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation

Feb 24

Bausch Health: $20bn Debt Is A Mighty Elephant In The Room

Nov 30

Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?

Nov 01
Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?

Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics

Sep 24

Is Bausch Health Companies (NYSE:BHC) A Risky Investment?

Jul 24
Is Bausch Health Companies (NYSE:BHC) A Risky Investment?

Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes

Jul 06

What To Do After Bausch Health Stock Plunged By Nearly 9% Again

Jun 07

Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt

Apr 18
Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt

Bausch Health: A Basket Case Of A Business Only A Hedge Fund Can Bail Out

Dec 30

Bausch Health acne lotion Arazlo available in Canada under public drug plans

Dec 22

Bausch Health: Things To Consider Before Investing

Dec 11

Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues

Nov 10
Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues

Bausch Health Companies Q3 2022 Earnings Preview

Nov 02

Bausch Health: Long-Term Need To Place Stops For Protection

Sep 28

Bausch Health Companies: Equity Stub Would Benefit From Ambitious Spinoff

Sep 21

Bausch Health sheds 10% as FDA grants tentative approval for Xifaxan generic

Sep 08

Bausch Health begin offers to exchange debt up to $4B

Aug 31

Bausch Health Stock Down 11%: Now What?

Aug 09

CEO 보상 분석

Tom Appio 의 보수는 Bausch Health Companies 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$455m

Dec 31 2023US$16mUS$1m

-US$592m

Sep 30 2023n/an/a

-US$963m

Jun 30 2023n/an/a

-US$186m

Mar 31 2023n/an/a

-US$357m

Dec 31 2022US$13mUS$1m

-US$225m

Sep 30 2022n/an/a

US$254m

Jun 30 2022n/an/a

US$43m

Mar 31 2022n/an/a

-US$407m

Dec 31 2021US$10mUS$854k

-US$948m

Sep 30 2021n/an/a

-US$1b

Jun 30 2021n/an/a

-US$1b

Mar 31 2021n/an/a

-US$1b

Dec 31 2020US$4mUS$775k

-US$560m

Sep 30 2020n/an/a

-US$2b

Jun 30 2020n/an/a

-US$2b

Mar 31 2020n/an/a

-US$2b

Dec 31 2019US$4mUS$769k

-US$2b

Sep 30 2019n/an/a

-US$616m

Jun 30 2019n/an/a

-US$917m

Mar 31 2019n/an/a

-US$2b

Dec 31 2018US$4mUS$730k

-US$4b

Sep 30 2018n/an/a

-US$3b

Jun 30 2018n/an/a

-US$2b

Mar 31 2018n/an/a

-US$805m

Dec 31 2017US$3mUS$650k

US$2b

보상 대 시장: Tom 의 총 보상 ($USD 15.88M )은 US 시장( $USD 5.67M ).

보상과 수익: 회사가 수익성이 없는 동안 Tom 의 보상이 증가했습니다.

CEO

Tom Appio (62 yo)

2.1yrs

테뉴어

US$15,878,578

보상

Mr. Thomas J. Appio, also known as Tom, serves as the Chief Executive Officer & Director at Bausch Health Companies Inc. and served as Chief Executive Officer of Pharma Business and served as President & C...

리더십 팀

이름위치테뉴어보상소유권
Thomas Appio
CEO & Director2.1yrsUS$15.88m0.11%
$ 2.9m
John Barresi
Senior VP2yrsUS$1.40m0.0055%
$ 137.7k
Seana Carson
Executive VP & General Counsel2.1yrsUS$3.16m0.023%
$ 562.1k
Mirza Dautbegovic
Executive VP & COO2.4yrs데이터 없음0.024%
$ 606.2k
Kathleen Fitzpatrick
Executive VP and Chief HR & Communications Officer2.4yrs데이터 없음데이터 없음
Josh Coyle
Senior Vice President of Sales & Salix1.4yrs데이터 없음데이터 없음
Tage Ramakrishna
Chief Medical Officer and President of R&Dno data데이터 없음데이터 없음
Jeff Hartness
Executive VP of Market Access4yrs데이터 없음데이터 없음
Graham Jackson
Senior VP & Chief Quality Officer2.4yrs데이터 없음데이터 없음
Cees Heiman
Senior Vice President of Europe & Canada2.4yrs데이터 없음데이터 없음
Donald Pearl
Senior Vice President of Ortho Dermatologicsno data데이터 없음데이터 없음
Jiny Kim
Senior Vice President of Solta Medical1.4yrs데이터 없음데이터 없음

2.3yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 관리: BHC 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Thomas Appio
CEO & Director2.1yrsUS$15.88m0.11%
$ 2.9m
John Paulson
Independent Chairman2yrsUS$812.50k0.000060%
$ 1.5k
Robert Power
Independent Director15.8yrsUS$389.55k0.0018%
$ 44.8k
H. Fibiger
Chairman of External Advisory Boardno dataUS$2.00m데이터 없음
Sarah Kavanagh
Independent Director7.9yrsUS$718.28k0%
$ 0
Robert Lenox
Member of the External Advisory Board15.3yrs데이터 없음데이터 없음
Kathleen Clarence-Smith
Member of the External Advisory Board15.3yrs데이터 없음데이터 없음
Karoly Nikolich
Member of the External Advisory Board15.3yrs데이터 없음데이터 없음
Brett Icahn
Independent Director3.3yrsUS$691.72k0.00020%
$ 5.0k
Amy Wechsler
Independent Director8yrsUS$377.50k0.011%
$ 286.2k
Steven Miller
Independent Director3.3yrsUS$381.31k0.031%
$ 766.3k
Christian Garcia
Independent Directorless than a year데이터 없음데이터 없음

7.9yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: BHC 의 이사회는 경험(평균 재직 기간 7.9 년)으로 간주됩니다.